Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

NCT04959032 is registered in ClinicalTrials.gov with Intra-Cellular Therapies, Inc. as lead sponsor.

NCT NCT04959032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04959032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
Lead sponsor
Intra-Cellular Therapies, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2021
Completion date
August 7, 2024
Enrollment
592 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia